Determinants of Variable Response to Statin Treatment in Patients With Refractory Familial Hypercholesterolemia
- 1 May 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 21 (5) , 832-837
- https://doi.org/10.1161/01.atv.21.5.832
Abstract
Abstract —Interindividual variability in low density lipoprotein (LDL) cholesterol (LDL-C) response during treatment with statins is well documented but poorly understood. To investigate potential metabolic and genetic determinants of statin responsiveness, 19 patients with refractory heterozygous familial hypercholesterolemia were sequentially treated with placebo, atorvastatin (10 mg/d), bile acid sequestrant, and the 2 combined, each for 4 weeks. Levels of LDL-C, mevalonic acid (MVA), 7-α-OH-4-cholesten-3-one, and leukocyte LDL receptor and hydroxymethylglutaryl coenzyme A reductase mRNA were determined after each treatment period. Atorvastatin (10 mg/d) reduced LDL-C by an overall mean of 32.5%. Above-average responders (ΔLDL-C −39.5%) had higher basal MVA levels (34.4±6.1 μmol/L) than did below-average responders (ΔLDL-C −23.6%, P P P P <0.05). Severe mutations were not more common in poor than in good responders. We conclude that poor responders to statins have a low basal rate of cholesterol synthesis that may be secondary to a genetically determined increase in cholesterol absorption, possibly mediated by apolipoprotein E4. If so, statin responsiveness could be enhanced by reducing dietary cholesterol intake or inhibiting absorption.Keywords
This publication has 30 references indexed in Scilit:
- Efficacy and safety of Simvastatin 80 mg/day in hypercholesterolemic patientsThe American Journal of Cardiology, 1998
- Is responsiveness to lovastatin in familial hypercholesterolaemia heterozygotes influenced by the specific mutation in the low‐density lipoprotein receptor gene?European Journal of Clinical Investigation, 1995
- Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low‐density‐lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatmentJournal of Internal Medicine, 1995
- Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in human mononuclear leukocytes is regulated coordinately and parallels gene expression in human liver.Journal of Clinical Investigation, 1994
- Apolipoprotein E phenotypes in familial hypercholesterolaemia: importance for expression of disease and response to therapyJournal of Internal Medicine, 1993
- Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemiaAtherosclerosis, 1993
- The plasma level of 7α‐hydroxy‐4‐cholesten‐3‐one reflects the activity of hepatic cholesterol 7α‐hydroxylase in manFEBS Letters, 1991
- Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemiaAtherosclerosis, 1990
- Regulation of the mevalonate pathwayNature, 1990
- Levels of 7α‐hydroxy‐4‐cholesten‐3‐one in plasma reflect rates of bile acid synthesis in manFEBS Letters, 1988